WP
APGE icon

Woodline Partners’s Apogee Therapeutics APGE Stock Holding History

Woodline Partners’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.7M Buy
464,622
+203,502
+78% +$18.3M 0.19% 135
2026
Q1 		$22M Buy
261,120
+50,654
+24% +$3.68M 0.08% 318
2025
Q4 		$15.9M Buy
210,466
+153,145
+267% +$9.65M 0.06% 357
2025
Q3 		$2.28M Sell
57,321
-812,887
-93% -$31M 0.01% 711
2025
Q2 		$37.8M Sell
870,208
-190,845
-18% -$7.26M 0.2% 144
2025
Q1 		$39.6M Buy
1,061,053
+45,445
+4% +$1.76M 0.26% 118
2024
Q4 		$46M Buy
1,015,608
+39,453
+4% +$2.01M 0.31% 90
2024
Q3 		$57.3M Buy
976,155
+229,996
+31% +$11M 0.48% 51
2024
Q2 		$29.4M Buy
746,159
+43,738
+6% +$2.12M 0.28% 113
2024
Q1 		$46.7M Buy
702,421
+376,319
+115% +$16.4M 0.43% 62
2023
Q4 		$9.11M Buy
326,102
+16,102
+5% +$323K 0.1% 239
2023
Q3 		$6.6M Buy
+310,000
New +$6.83M 0.08% 275

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Woodline Partners's APGE Position: Q2 2026 in Review

Woodline Partners increased its Apogee Therapeutics (APGE) stake by 78% in Q2 2026, buying an estimated $18.3M and bringing the position to 464,622 shares worth $61.7M. The position accounts for 0.19% of the portfolio, ranked #135.

Woodline Partners first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Woodline Partners held 464,622 shares of Apogee Therapeutics worth $61.7M as of Q2 2026.
  • Woodline Partners bought 203,502 Apogee Therapeutics shares in Q2 2026, an estimated $18.3M.
  • Apogee Therapeutics made up 0.19% of Woodline Partners's portfolio in Q2 2026, its #135 holding.
  • Woodline Partners first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.